Nature Reviews Cardiology

(The TQCC of Nature Reviews Cardiology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives941
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions587
Myocardial ischaemia–reperfusion injury and cardioprotection in perspective577
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension533
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control382
Environmental determinants of cardiovascular disease: lessons learned from air pollution371
Interplay between inflammation and thrombosis in cardiovascular pathology357
Smart wearable devices in cardiovascular care: where we are and how to move forward332
PPAR control of metabolism and cardiovascular functions320
Artificial intelligence-enhanced electrocardiography in cardiovascular disease management319
Global epidemiology of dyslipidaemias304
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation285
Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases283
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease268
Cardiac natriuretic peptides265
Epidemiology of cardiovascular disease in Europe253
Pathophysiology of sepsis-induced cardiomyopathy249
Native and bioengineered extracellular vesicles for cardiovascular therapeutics230
Global epidemiology of valvular heart disease230
Transportation noise pollution and cardiovascular disease217
Self-powered cardiovascular electronic devices and systems205
Cellular and molecular pathobiology of heart failure with preserved ejection fraction196
Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6192
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium182
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis179
Epicardial adipose tissue in contemporary cardiology175
Cardiovascular disease in patients with severe mental illness165
Ceramides and other sphingolipids as drivers of cardiovascular disease164
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms163
Heart failure with mid-range or mildly reduced ejection fraction160
Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes158
The role of cardiac rehabilitation in improving cardiovascular outcomes157
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging147
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment143
Systems biology in cardiovascular disease: a multiomics approach140
Lifestyle interventions for the prevention and treatment of hypertension131
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches130
Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity130
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?129
Epidemiology of the inherited cardiomyopathies127
Sit less and move more for cardiovascular health: emerging insights and opportunities125
The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy119
Optical coherence tomography in coronary atherosclerosis assessment and intervention119
Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management118
Pregnancy and cardiovascular disease110
Genomics of hypertension: the road to precision medicine105
High-density lipoproteins, reverse cholesterol transport and atherogenesis98
Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target98
Cardiac optogenetics: a decade of enlightenment96
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development94
Apolipoproteins in vascular biology and atherosclerotic disease94
Genomic frontiers in congenital heart disease93
Transforming growth factor-β in myocardial disease93
The role of cellular senescence in cardiac disease: basic biology and clinical relevance91
Blood pressure and its variability: classic and novel measurement techniques90
Catheter ablation for atrial fibrillation: current indications and evolving technologies85
Mechanisms and consequences of endothelial cell senescence84
Complete versus incomplete coronary revascularization: definitions, assessment and outcomes81
Cardiovascular risks of climate change81
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease80
Applications of artificial intelligence in cardiovascular imaging79
Climate change and cardiovascular disease: implications for global health77
Cardiac involvement in the long-term implications of COVID-1975
Vascular endothelial cell development and diversity74
RNA-targeting and gene editing therapies for transthyretin amyloidosis72
Sulfide regulation of cardiovascular function in health and disease71
Bleeding avoidance strategies in percutaneous coronary intervention71
Update on the pathophysiology and medical treatment of peripheral artery disease69
The role of mitochondrial fission in cardiovascular health and disease69
Myocardial stunning and hibernation revisited69
Social determinants of atrial fibrillation67
Epidemiology and prevention of venous thromboembolism66
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia66
Branched-chain amino acids in cardiovascular disease65
Clinical utility of polygenic risk scores for coronary artery disease64
Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions63
Epidemiology and modifiable risk factors for atrial fibrillation63
Obesity and the risk of cardiometabolic diseases62
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology61
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action59
Targeted delivery of therapeutic agents to the heart58
A fresh look at coronary microembolization57
Immune cell profiling in atherosclerosis: role in research and precision medicine57
Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs54
The evolving cardiac lymphatic vasculature in development, repair and regeneration54
Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications53
Pharmacogenetics to guide cardiovascular drug therapy52
Prevention of atherosclerosis from childhood52
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies49
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective49
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia47
The health digital twin: advancing precision cardiovascular medicine47
Targeting the sarcomere in inherited cardiomyopathies45
Hallmarks of cardiovascular ageing43
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications42
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management42
Electroimmunology and cardiac arrhythmia41
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism40
Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease38
Macrophages in cardiac remodelling after myocardial infarction38
Obstructive sleep apnoea heterogeneity and cardiovascular disease38
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes38
Increasing representation and diversity in cardiovascular clinical trial populations37
Towards precision medicine in heart failure37
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing37
The COVID-19 pandemic: a catalyst to improve clinical trials36
Stroke prevention strategies in high-risk patients with atrial fibrillation36
Remote monitoring and digital health tools in CVD management35
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization35
Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets35
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention35
Coronary vessel formation in development and disease: mechanisms and insights for therapy34
Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities33
The microtubule cytoskeleton in cardiac mechanics and heart failure33
The contribution of the exposome to the burden of cardiovascular disease33
Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research33
The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease33
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer31
The oral microbiome in the pathophysiology of cardiovascular disease30
Cardiac fibroblasts and mechanosensation in heart development, health and disease30
Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome29
Mitral valve regurgitation: a disease with a wide spectrum of therapeutic options29
Repurposing drugs to treat cardiovascular disease in the era of precision medicine29
Improving clinical practice guidelines with implementation science27
Effects of fatty acids on T cell function: role in atherosclerosis27
Calcific aortic valve disease: mechanisms, prevention and treatment27
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention26
Single-cell transcriptomics for the assessment of cardiac disease26
A change of heart: new roles for cilia in cardiac development and disease25
Temporary mechanical circulatory support devices: practical considerations for all stakeholders25
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease25
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure24
Pathophysiology and risk factors of peripartum cardiomyopathy24
Hypertension in China: epidemiology and treatment initiatives24
Flow-induced reprogramming of endothelial cells in atherosclerosis23
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential23
Reduced hospital admissions for ACS — more collateral damage from COVID-1923
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults23
Interventional therapies for pulmonary embolism22
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications22
Plastics and cardiovascular disease22
Genetics and mechanisms of thoracic aortic disease21
The need for increased pragmatism in cardiovascular clinical trials21
The use of new CRISPR tools in cardiovascular research and medicine21
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization19
The biology of atherosclerosis comes full circle: lessons for conquering cardiovascular disease19
Cardiovascular health and disease in migrant populations: a call to action18
Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges18
Genomic enhancers in cardiac development and disease18
Clarification of the definition of hypoplastic left heart syndrome18
Long COVID and cardiovascular disease: a learning health system approach18
Diversity 4.0 in the cardiovascular health-care workforce18
RAAS inhibitors do not increase the risk of COVID-1917
The role of aldehyde dehydrogenase 2 in cardiovascular disease17
Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group17
PCSK9-targeted therapies: present and future approaches16
Non-hyperaemic coronary pressure measurements to guide coronary interventions16
Developing a vaccine against atherosclerosis16
Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death15
Clonal haematopoiesis and atherosclerosis: a chicken or egg question?15
Mechanisms of ryanodine receptor 2 dysfunction in heart failure14
RNA modifications in cardiovascular health and disease14
Current and future applications of virtual reality technology for cardiac interventions14